← Return to Aromatase Inhibitors: Did you decide to go on them or not?

Discussion
Comment receiving replies
@windyshores

The Oncotype and Mammaprint are used when pathology is first done after surgery. The Breast Cancer Index is for deciding on continuing meds for years 5-10. They told me studies only covered that period of time but that since it showed no benefit for me from AI's for those years, I could maybe assume the same was true for years 1-5. However, after writing you before, I think it might be hard to get the Breast Cancer Index at this stage for you. The Oncotype is standard of care and in all the guidelines. I felt comfortable relying on it. The company reps are very informative and reassuring.

If I were you, I would try the aromatase inhibitor (I did Femara) and work with oncologist and endocrinologist on monitoring and possibly treating your bones.

I am sorry if I complicated things for you. AI's are very tolerable or even without side effects for many of us and with your scenario I am sure they will be very helpful.

Jump to this post


Replies to "The Oncotype and Mammaprint are used when pathology is first done after surgery. The Breast Cancer..."

You didn't complicate anything and I appreciate what I'm learning here as I am better prepared with even more questions for tomorrow's visit with oncologist. He's insufficiently informative and much of what I learned since surgery he should have addressed so I have his possible replacement lined up just in case. Also I have a letter from Oncotype correctly stating that the cohort pool for the OncotypeDX specifically precludes anyone who had radiation or chemo since the onco is adamant that the test assumes one first had radiation. I'm perturbed that this chief of staff for breast cancer oncology at an internationally top-ranked facility (not Mayo though) is citing invalid statistics even though I told him that Oncotype senior staff informed me correctly and he is misinformed. Now I have a letter from Oncotype stating that radiation is not assumed, which my PCP, breast surgeon and endocrinologist found surprising. [I wanted to assure them that I'm not a non-compliant patient but that the onco is just....well, wrong about what the OncotypeDX score means. And, yes, the OncotypeDX client support people have been excellent. I even received a call-back from a senior person on the science staff who reassured me that I understood correctly. And sent a follow-up email. He was dismayed that a lot of physicians are still incorrect about the protocol and information behind the test as he usually hears from doctors with questions. ].
Unrelated to the above, a friend, also a cancer patient, leaves her cell phone on audio record when she goes to a medical appointment alone so she can relisten later in case she misunderstood something or new information came up that she wanted to research later, including names of alternate drugs. Or side effects